March 22, 2006 09:30 ET

Nymox to Present at Dutton Associates' ''Recognizing Opportunity'' SmallCap Conference in San Francisco Mar. 28

HASBROUCK HEIGHTS, N.J.--(CCNMatthews - Mar 22, 2006) -

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) will present at Dutton Associates' "Recognizing Opportunity" SmallCap Conference. Nymox along with a select group of emerging growth companies in a variety of sectors, including energy, alternative energy, technology, security, financial services, and consumer products, will update investment professionals on business activities, trends and current developments.

The conference will take place at St. Regis Hotel in San Francisco on Tuesday, March 28 from 7:45 a.m. to 5 p.m. The Company will make a presentation in the morning. In the afternoon, Nymox will present to small, informal groups of investment professionals during two break-out sessions. For more conference information and registration, visit www.jmdutton.com.

Nymox Pharmaceutical Corporation is engaged in development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. The Company is conducting pivotal Phase II clinical trials for NX-1207 a drug for benign prostatic hyperplasia (BPH). Nymox has a number of drugs in development for E. coli infection, Alzheimer's disease, oncology, and infectious disease. The Company markets NicAlert™ and TobacAlert™ tests for measuring tobacco product exposure. Nymox offers AlzheimAlert™, a test to aid in the diagnosis of Alzheimer's disease.

About Dutton Associates

Dutton Associates, an international issuer-paid equity research firm, offers independent, fundamental research on over 120 small cap public companies. The company's 29 analysts are primarily CFA charterholders with, on average, over 20 years of experience at the major securities firms. For more information, visit www.jmdutton.com.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.

Contact Information

  • Nymox Pharmaceutical Corporation
    Roy Wolvin, 1-800-93NYMOX